2019
DOI: 10.2337/dc19-1177
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
35
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 49 publications
(44 citation statements)
references
References 5 publications
(7 reference statements)
4
35
1
Order By: Relevance
“…As reported previously 8 , the absolute change in RHI from baseline to 24 weeks was -0.006 -0.478 (empagliflozin) and - 0.025 -0.454 (placebo), with no significant intergroup difference observed (-0.020, 95% CI -0.199 to 0.158, P = 0.821).…”
Section: Detailed Effect Of Empagliflozin On Endothelial Functionsupporting
confidence: 81%
See 3 more Smart Citations
“…As reported previously 8 , the absolute change in RHI from baseline to 24 weeks was -0.006 -0.478 (empagliflozin) and - 0.025 -0.454 (placebo), with no significant intergroup difference observed (-0.020, 95% CI -0.199 to 0.158, P = 0.821).…”
Section: Detailed Effect Of Empagliflozin On Endothelial Functionsupporting
confidence: 81%
“…In this regard, whether a longer period of SGLT2 inhibitor treatment has clinically apparent benefits on vascular function and atherosclerosis needs to be examined in greater detail. The present study had several limitations in addition to those reported for the EMBLEM trial 8 . First, this secondary analysis might have been influenced by the post-randomization nature of the post-hoc analyses and the smaller number of participants.…”
Section: And Other Physiologicalmentioning
confidence: 65%
See 2 more Smart Citations
“…The effects of SGLT2 inhibitors on endothelial function, which is an arteriosclerosis-related change that occurs on a shorter timescale than IMT hyperplasia [41], were evaluated in earlier reports. In the double-blind RCT EMBLEM, the effect of empagliflozin on the reactive hyperemia peripheral arterial tonometry index, an indicator of endothelial function, was estimated; however, the change was not significant [42]. Similarly, in another study, dapagliflozin did not significantly affect the flow-mediated dilation, another indicator of endothelial function [10].…”
Section: Effects Of Tofogliflozin On Atherosclerosismentioning
confidence: 99%